Table 9 Selected studies for CML therapy from 2020 ASH annual meeting
Abstract # | Authors (reference) | Study | Phase | NCT |
|---|---|---|---|---|
46 | Brummendorf et al.[96] | Bosutinib versus imatinib | III | NCT02130557 |
45 | Matsumura et al. [97] | Nilotinib versus dasatinib | III | #UMIN000007909 |
632 | Cortes et al. [100] | Ponatinib | II | NCT02467270 |
650 | Cortes et al. [103] | Asciminib | I | NCT02081378 |
LBA-4 | Hochhaus et al. [104] | Asciminib versus bosutinib | III | NCT03106779 |
651 | Jiang et al. [108] | HQP1351 (Olverembatinib) | II | NCT03883087 NCT03883100 |
652 | Cortes et al. [109] | Vodobatinib | I | NCT02629692 |